DOCSLIB.ORG

A Review on Fast Dissolving Tablets

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Review on Fast Dissolving Tablets Article ID: WMC00809 ISSN 2046-1690 A Review on Fast Dissolving Tablets Corresponding Author: Mrs. Rajeshree Panigrahi, Lecturer, Royal College of Pharmacy and Health Sciences, 760001 - India Submitting Author: Mrs. Rajeshree Panigrahi, Lecturer, Royal College of Pharmacy and Health Sciences, 760001 - India Article ID: WMC00809 Article Type: Review articles Submitted on:29-Sep-2010, 10:18:47 AM GMT Published on: 29-Sep-2010, 02:48:11 PM GMT Article URL: http://www.webmedcentral.com/article_view/809 Subject Categories:QUALITY AND PATIENT SAFETY Keywords:A drug which gives no tension of swallowing, Bad taste fit for all How to cite the article:Panigrahi R , Behera S . A Review on Fast Dissolving Tablets . WebmedCentral QUALITY AND PATIENT SAFETY 2010;1(9):WMC00809 WebmedCentral > Review articles Page 1 of 15 WMC00809 Downloaded from http://www.webmedcentral.com on 16-Feb-2012, 06:39:30 AM A Review on Fast Dissolving Tablets Author(s): Panigrahi R , Behera S Abstract patient compliance. Many patients have difficulty swallowing tablets and hard gelatin capsules and consequently do not take medications as prescribed. It is estimated that50% of the population is affected by Recently, fast-dissolving drug delivery systems have this problem, which results in a high incidence of started gaining popularity and acceptance as new drug noncompliance and ineffective therapy. The demand delivery systems, because they are easy to administer for solid dosage forms that can be dissolved and and lead to better patient compliance. Usually, elderly suspended in water, chewed, or rapidly dissolved in people experience difficulty in swallowing the the mouth is particularly strong in the pediatric and conventional dosage forms (tablets, capsules, geriatric markets, with further application to other solutions and suspensions) because of tremors of patients who prefer the convenience of a readily extremities and dysphasia. Fast-dissolving drug administered dosage form. Because of the increase in delivery systems may offer a solution for these the average human life span and the decline, with age, problems. in swallowing ability, oral tablet administration to Key Words: Fast Dissolving Tablet, drug delivery patients is a significant problem and has become the system object of public attention. The problem can be Introduction resolved by the creation of rapidly dispersing or dissolving oral forms, which do not require water to aid swallowing. The dosages forms are placed in the Drug delivery systems (DDS) are a strategic tool for mouth, allowed to disperse or dissolve in the saliva, expanding markets/indications, extending product life and then are swallowed in the normal way. Less cycles and generating opportunities. Oral frequently, they are designed to be absorbed through administration is the most popular route for systemic the buccal and esophageal mucosa as the saliva effects due to its ease of ingestion, pain, avoidance, passé into the stomach. In the latter case, the versatility and most importantly, patient compliance. bioavailability of a drug from fast dispersing Also solid oral delivery systems do not require sterile formulations may be even greater than that observed conditions and are therefore, less expensive to for standard dosage forms. manufacture. Patient compliance, high-precision The concept of Mouth Dissolving Drug Delivery dosing, and manufacturing efficiency make tablets the System emerged from the desire to provide patient solid dosage form of choice .Excipients and with more conventional means of taking their equipments choices will be significantly affected medication. It is difficult for many patients to swallow should solid dosage form technologies change in tablets and hard gelatin capsules. Hence they do not response to the unprecedented shifts in the drug comply with prescription, which results in high discovery such as genomics. Should next generation incidence of non-compliance and ineffective therapy. drugs are predominantly protein or peptide based, In some cases such as motion sickness, sudden tablets may no longer may be the dominant format episodes of allergic attacks or coughing and give the difficulty of dosing such moiety. Injections unavailability of water, swallowing conventional tablets generally are not favored for use by patients unless may be difficult. Particularly the difficulty is facilitated by sophisticated auto injectors. Inhalation is experienced by pediatric and geriatric patients. Such one good alternative system to deliver these drugs, problems can be resolved by means of Fast Dissolving but the increased research into biopharmaceuticals so Tablet. When put on tongue, this tablet disintegrates far has generate predominantly chemical entities with instantaneously, releasing the drug, which dissolves or low molecular weights. The development of enhanced disperses in the saliva. Some drugs are absorbed from oral protein delivery technology by Fast dissolving the mouth, pharynx and esophagus as the saliva Tablets which may release these drugs in the mouth passes down into the stomach. In such cases, are very promising for the delivery of high molecular bioavailability of drug is significantly greater than those weight protein and peptide. The oral route remains the observed from conventional tablet dosage form. perfect route for the administration of therapeutic FDDTs disintegrate and/or dissolve rapidly in the agents because the low cost of therapy, manufacturing saliva without the need for water. Some tablets are and ease of administration lead to high levels of designed to dissolve in saliva remarkably fast, within a WebmedCentral > Review articles Page 2 of 15 WMC00809 Downloaded from http://www.webmedcentral.com on 16-Feb-2012, 06:39:30 AM few seconds, and are true fast-dissolving tablets. granules which slowly dissolve in the mouth. The Others contain agents to enhance the rate of tablet disintegration time for fast dissolving tablet varies from disintegration in the oral cavity, and are more a few seconds to more than a minute depending on appropriately termed fast-disintegrating tablets, as the formulation and the size of the tablet. they may take up to a minute to completely A fast disintegrating or dissolving system or tablet can disintegrate. When put on tongue, this tablet be defined as a solid dosage form that can disintegrates instantaneously, releasing the drug, disintegrate or dissolve within 30 seconds, in the oral which dissolves or disperses in the saliva. Some drugs cavity resulting in a solution or suspension without are absorbed from the mouth, pharynx and esophagus administration of water. The fast disintegrating tablets as the saliva passes down into the stomach. In such are synonymous with fast dissolving tablets; melt in cases, bioavailability of drug is significantly greater mouth tablets, rapimelts, Porous tablets, than those observed from conventional tablet dosage Orodispersible, quick dissolving or rapidly form.FDDTs, as a novel dosage form, have several disintegrating tablets. Their growing importance was characteristics to distinguish them from the more underlined recently when European pharmacopoeia traditional dosage forms. Taste-masking is of critical adopted the term “Orodispersible tablet” as a tablet importance in the formulation of an acceptable FDDT. that to be placed in the mouth where it disperses Traditional tablet formulations generally do not rapidly, before swallowing significance of this drug address the issue of taste masking, because it is delivery system includes administration without water, assumed that the dosage form will not dissolve until accuracy dosage, easy portability, alternative to liquid passing the oral cavity. Many oral suspensions, syrups, dosage forms ideal for pediatrics’ & geriatric patients and chewable tablets simply contain flavors, sugars and rapid onset of action. and other sweeteners to overwhelm or complement the bitter taste of the drug. Current methods of taste Biopharmaceutic masking in fast dissolving/ drug particles.FDTs are the Consideration disintegrating tablets include sweeteners and flavors; however, these are not a sufficient means for taste-masking many bitter drugs. Most of the FDDT When new drug delivery system put on, it is must that technologies incorporate unique forms of taste to consider Biopharmaceutical factor like metabolism masking as well. The primary methods of and excretion. taste-masking include adsorption onto or complexation Pharmacokinetics: with carriers and spray coating of solid dosage forms, In this consideration, study has done on absorption, which increase consumer choice, for the reason of distribution, metabolism and excretion. rapid disintegrate/dissolve in oral cavity within seconds After absorption, drug attains therapeutic level and and swallowed without the need of water or chewing. therefore elicits pharmacological effect, so both rate As tablet disintegrates in mouth this could enhance the and extend of absorption is important. In conventional clinical effect of the drug through pre-gastric dosage form there is delay in disintegration and absorption from the mouth, pharynx and esophagus. therefore dissolution while FDT is rapidly disintegrates This leads to an increase in bioavailability by avoiding in oral cavity and dissolution is fast. Due to first pass metabolism. disintegration of FDT in mouth absorption in started Fast dissolving drug delivery can be achieved various from mouth, pharynx and esophagus. Some factors techniques like direct compression, wet granulation,
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Chemotherapy of Gastrointestinal Helminths
    Chemotherapy of Gastrointestinal Helminths Contributors J. H. Arundel • J. H. Boersema • C. F. A. Bruyning • J. H. Cross A. Davis • A. De Muynck • P. G. Janssens • W. S. Kammerer IF. Michel • M.H. Mirck • M.D. Rickard F. Rochette M. M. H. Sewell • H. Vanden Bossche Editors H. Vanden Bossche • D.Thienpont • P.G. Janssens UNIVERSITATS- BlfiUOTHElC Springer-Verlag Berlin Heidelberg New York Tokyo Contents CHAPTER 1 Introduction. A. DAVIS A. Pathogenic Mechanisms in Man 1 B. Modes of Transmission 2 C. Clinical Sequelae of Infection 3 D. Epidemiological Considerations 3 E. Chemotherapy 4 F. Conclusion 5 References 5 CHAPTER 2 Epidemiology of Gastrointestinal Helminths in Human Populations C. F. A. BRUYNING A. Introduction 7 B. Epidemiological or "Mathematical" Models and Control 8 C. Nematodes 11 I. Angiostrongylus costaricensis 11 II. Anisakis marina 12 III. Ascaris lumbricoides 14 IV. Capillaria philippinensis 21 V. Enterobius vermicularis 23 VI. Gnathostoma spinigerum 25 VII. Hookworms: Ancylostoma duodenale and Necator americanus . 26 VIII. Oesophagostoma spp 32 IX. Strongyloides stercoralis 33 X. Ternidens deminutus 34 XI. Trichinella spiralis 35 XII. Trichostrongylus spp 38 XIII. Trichuris trichiura 39 D. Trematodes 41 I. Echinostoma spp 41 II. Fasciolopsis buski 42 III. Gastrodiscoides hominis 44 IV. Heterophyes heterophyes 44 V. Metagonimus yokogawai 46 X Contents E. Cestodes 47 I. Diphyllobothrium latum 47 II. Dipylidium caninum 50 III. Hymenolepis diminuta 51 IV. Hymenolepis nana 52 V. Taenia saginata 54 VI. Taenia solium 57 VII. Cysticercosis cellulosae 58 References 60 CHAPTER 3 Epidemiology and Control of Gastrointestinal Helminths in Domestic Animals J. F. MICHEL. With 20 Figures A. Introduction 67 I.
    [Show full text]
  • Anthelmintic Resistance of Ostertagia Ostertagi and Cooperia Oncophora to Macrocyclic Lactones in Cattle from the Western United States
    Veterinary Parasitology 170 (2010) 224–229 Contents lists available at ScienceDirect Veterinary Parasitology journal homepage: www.elsevier.com/locate/vetpar Anthelmintic resistance of Ostertagia ostertagi and Cooperia oncophora to macrocyclic lactones in cattle from the western United States M.D. Edmonds, E.G. Johnson, J.D. Edmonds ∗ Johnson Research LLC, 24007 Highway 20-26, Parma, ID, 83660, USA article info abstract Article history: In June 2008, 122 yearling heifers with a history of anthelmintic resistance were obtained Received 15 October 2009 from pastures in northern California and transported to a dry lot facility in southwest- Received in revised form 28 January 2010 ern Idaho, USA. Fifty heifers with the highest fecal egg counts were selected for study Accepted 24 February 2010 enrollment. Candidates were equally randomized to treatment with either injectable iver- mectin (Ivomec®, Merial, 0.2 mg kg−1 BW), injectable moxidectin (Cydectin®, Fort Dodge, Keywords: 0.2 mg kg−1 BW), oral fenbendazole (Safe-Guard®, Intervet, 5.0 mg kg−1 BW), oral oxfenda- Anthelmintic resistance zole (Synanthic®, Fort Dodge, 4.5 mg kg−1 BW), or saline. At 14 days post-treatment, Cattle Bovine nematodes were recovered from the abomasum, small intestine, and large intestine. Par- Nematodes asitism was confirmed in the control group when 10/10 animals were infected with Efficacy adult Ostertagia ostertagi and 9/10 animals with both developing and early L4 stages of Cooperia O. ostertagi. Similarly, 9/10 animals were parasitized with adult Cooperia spp. Fenbenda- Ostertagia zole and oxfendazole efficacy verses controls were >90% against adult Cooperia spp., while moxidectin caused an 88% parasite reduction post-treatment (P < 0.05).
    [Show full text]
  • H1-Antihistamines for Chronic Spontaneous Urticaria: an Abridged Cochrane Systematic Review
    H1-antihistamines for chronic spontaneous urticaria: An abridged Cochrane Systematic Review Sharma, Maulina , Bennett, C. , Carter, Ben and Cohen, Stuart N. Author post-print (accepted) deposited by Coventry University’s Repository Original citation & hyperlink: Sharma, Maulina , Bennett, C. , Carter, Ben and Cohen, Stuart N. (2015) H1-antihistamines for chronic spontaneous urticaria: An abridged Cochrane Systematic Review . Journal of the American Academy of Dermatology, volume 73 (4): 710-716 http://dx.doi.org/10.1016/j.jaad.2015.06.048 DOI 10.1016/j.jaad.2015.06.048 ISSN 0190-9622 ESSN 1097-6787 Publisher: Elsevier NOTICE: this is the author’s version of a work that was accepted for publication in Journal of the American Academy of Dermatology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of the American Academy of Dermatology, [VOL 73, ISSUE 4, (2015)] DOI: 10.1016/j.jaad.2015.06.048 © 2015, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ Copyright © and Moral Rights are retained by the author(s) and/ or other copyright owners. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This item cannot be reproduced or quoted extensively from without first obtaining permission in writing from the copyright holder(s). The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the copyright holders.
    [Show full text]
  • Tor Amendment Tagoor Laboratories Private Limited
    ToR Amendment Tagoor Laboratories Private Limited ANNEXURE – I Details of Products as per Granted ToR and Amendment Required Production Capacity S. Ton /Month Therapeutic Product Name No As per Amendment category granted ToR Required 1 Abacavir sulfate 2.0 2.0 Anti HIV 2 Amitriptyline 5.0 10.0 Antidepressant 3 Atrovastatin Calcium 5.0 5.0 Hypercholesterolemia 4 Bupropion 5.0 5.0 Anti depressant 5 carisoprodol 2.0 2.0 Muscle Relaxant 6 Clopidogrelbisulfate 5.0 5.0 Antithrombotic 7 Cyclobenzaprine HCl 5.0 5.0 Muscle relaxant 8 Cyproheptadine HCl 5.0 10.0 Anti allergic 9 Desloratadine 5.0 5.0 Antihistamine 10 Domperidone 20.0 30.0 Anti emetic 11 Domperidone maleate 2.0 2.0 Anti emetic 12 Donepezil HCl 1.0 1.0 Alzheimer’s disease 13 Ebastine 5.0 5.0 Anti allergic 14 Esomeprazole Sodium 3.0 3.0 Anti ulcerative Esomeprazole Magnesium 3.0 3.0 Anti ulcerative 15 trihydrate 16 Fexofenadine Hydrochloride 6.0 15.0 Anti histamine 17 Haloperidol 2.0 2.0 Antipsychotic 18 Itopride Hydrochloride 2.0 2.0 Antispasmodics 19 Itraconazole 10.0 10.0 Antifungal 20 Ketrolac Tromethane 2.0 2.0 Anti Inflammatory 21 Lansoprazole 10.0 10.0 Ant ulcerative 22 Loperamide Hydrochloride 10.0 10.0 Anti diarrhea agent 23 Losartan Potassium 6.0 15.0 Anti Hypertensive 24 Nebivolol HCl 2.0 2.0 Anti Hypertensive 25 Nortriptyline HCl 2.0 2.0 Anti depressant 26 Omeprazole 40.0 40.0 Anti ulcerative 27 Omeprazole Sodium 2.0 2.0 Ant ulcerative Omeprazole Magnesium 2.0 2.0 Ant ulcerative 28 Dihydrate 29 Oxatomide 1.0 1.0 Antihistamine Pantoprazole Sodium Sesqui 10.0 20.0 Ant ulcerative 30 Hydrate 31 Pimozide 2.0 2.0 Antipsychotic 32 Pregabalin 2.0 2.0 Epileptic 33 Quetiapine Hemifumarate 2.0 2.0 Antipsychotic Prepared By Rightsource Industrial Solutions Pvt.
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/107 (2006.01) A61K 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A 61 47/10 (2006.0V) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/US2012/034361 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 20 April 2012 (20.04.2012) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/480,259 28 April 201 1 (28.04.201 1) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant (for all designated States except US): BOARD UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, OF REGENTS, THE UNIVERSITY OF TEXAS SYS¬ TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, TEM [US/US]; 201 West 7th St., Austin, TX 78701 (US).
    [Show full text]
  • Modelling for Taenia Solium Control
    PolicyPolicy & practice & practice Modelling for Taenia solium control strategies beyond 2020 Matthew A Dixon,a Uffe C Braae,b Peter Winskill,a Brecht Devleesschauwer,c Chiara Trevisan,d Inge Van Damme,e Martin Walker,f Jonathan I D Hamley,a Sylvia N Ramiandrasoa,g Veronika Schmidt,h Sarah Gabriël,e Wendy Harrisoni & Maria-Gloria Basáñeza Abstract The cestode Taenia solium is responsible for a considerable cross-sectoral health and economic burden due to human neurocysticercosis and porcine cysticercosis. The 2012 World Health Organization (WHO) roadmap for neglected tropical diseases called for the development of a validated strategy for control of T. solium; however, such a strategy is not yet available. In 2019, WHO launched a global consultation aimed at refining the post-2020 targets for control of T. solium for a new roadmap for neglected tropical diseases. In response, two groups working on taeniasis and cysticercosis mathematical models (cystiSim and EPICYST models), together with a range of other stakeholders organized a workshop to provide technical input to the WHO consultation and develop a research plan to support efforts to achieve the post-2020 targets. The workshop led to the formation of a collaboration, CystiTeam, which aims to tackle the population biology, transmission dynamics, epidemiology and control of T. solium through mathematical modelling approaches. In this paper, we outline developments in T. solium control and in particular the use of modelling to help achieve post-2020 targets for control of T. solium. We discuss the steps involved in improving confidence in the predictive capacities of existing mathematical and computational models on T.
    [Show full text]
  • Screening of 300 Drugs in Blood Utilizing Second Generation
    Forensic Screening of 300 Drugs in Blood Utilizing Exactive Plus High-Resolution Accurate Mass Spectrometer and ExactFinder Software Kristine Van Natta, Marta Kozak, Xiang He Forensic Toxicology use Only Drugs analyzed Compound Compound Compound Atazanavir Efavirenz Pyrilamine Chlorpropamide Haloperidol Tolbutamide 1-(3-Chlorophenyl)piperazine Des(2-hydroxyethyl)opipramol Pentazocine Atenolol EMDP Quinidine Chlorprothixene Hydrocodone Tramadol 10-hydroxycarbazepine Desalkylflurazepam Perimetazine Atropine Ephedrine Quinine Cilazapril Hydromorphone Trazodone 5-(p-Methylphenyl)-5-phenylhydantoin Desipramine Phenacetin Benperidol Escitalopram Quinupramine Cinchonine Hydroquinine Triazolam 6-Acetylcodeine Desmethylcitalopram Phenazone Benzoylecgonine Esmolol Ranitidine Cinnarizine Hydroxychloroquine Trifluoperazine Bepridil Estazolam Reserpine 6-Monoacetylmorphine Desmethylcitalopram Phencyclidine Cisapride HydroxyItraconazole Trifluperidol Betaxolol Ethyl Loflazepate Risperidone 7(2,3dihydroxypropyl)Theophylline Desmethylclozapine Phenylbutazone Clenbuterol Hydroxyzine Triflupromazine Bezafibrate Ethylamphetamine Ritonavir 7-Aminoclonazepam Desmethyldoxepin Pholcodine Clobazam Ibogaine Trihexyphenidyl Biperiden Etifoxine Ropivacaine 7-Aminoflunitrazepam Desmethylmirtazapine Pimozide Clofibrate Imatinib Trimeprazine Bisoprolol Etodolac Rufinamide 9-hydroxy-risperidone Desmethylnefopam Pindolol Clomethiazole Imipramine Trimetazidine Bromazepam Felbamate Secobarbital Clomipramine Indalpine Trimethoprim Acepromazine Desmethyltramadol Pipamperone
    [Show full text]
  • Sheet1 Page 1 a Abamectin Acetazolamide Sodium Adenosine-5-Monophosphate Aklomide Albendazole Alfaxalone Aloe Vera Alphadolone A
    Sheet1 A Abamectin Acetazolamide sodium Adenosine-5-monophosphate Aklomide Albendazole Alfaxalone Aloe vera Alphadolone Acetate Alpha-galactosidase Altrenogest Amikacin and its salts Aminopentamide Aminopyridine Amitraz Amoxicillin Amphomycin Amphotericin B Ampicillin Amprolium Anethole Apramycin Asiaticoside Atipamezole Avoparcin Azaperone B Bambermycin Bemegride Benazepril Benzathine cloxacillin Benzoyl Peroxide Benzydamine Bephenium Bephenium Hydroxynaphthoate Betamethasone Boldenone undecylenate Boswellin Bromelain Bromhexine 2-Bromo-2-nitropan-1, 3 diol Bunamidine Buquinolate Butamisole Butonate Butorphanol Page 1 Sheet1 C Calcium glucoheptonate (calcium glucoheptogluconate) Calcium levulinate Cambendazole Caprylic/Capric Acid Monoesters Carbadox Carbomycin Carfentanil Carnidazole Carnitine Carprofen Cefadroxil Ceftiofur sodium Centella asiatica Cephaloridine Cephapirin Chlorine dioxide Chlormadinone acetate Chlorophene Chlorothiazide Chlorpromazine HCl Choline Salicylate Chondroitin sulfate Clazuril Clenbuterol Clindamycin Clomipramine Clopidol Cloprostenol Clotrimazole Cloxacillin Colistin sulfate Copper calcium edetate Copper glycinate Coumaphos Cromolyn sodium Crystalline Hydroxycobalamin Cyclizine Cyclosporin A Cyprenorphine HCl Cythioate D Decoquinate Demeclocycline (Demethylchlortetracycline) Page 2 Sheet1 Deslorelin Desoxycorticosterone Pivalate Detomidine Diaveridine Dichlorvos Diclazuril Dicloxacillin Didecyl dimethyl ammonium chloride Diethanolamine Diethylcarbamazine Dihydrochlorothiazide Diidohydroxyquin Dimethylglycine
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,173.403 B2 Rosentel, Jr
    USOO9173403B2 (12) United States Patent (10) Patent No.: US 9,173.403 B2 Rosentel, Jr. et al. (45) Date of Patent: Nov. 3, 2015 (54) PARASITICIDAL COMPOSITIONS FOREIGN PATENT DOCUMENTS COMPRISING MULTIPLE ACTIVE AGENTS, BR PIO403620 A 3, 2006 METHODS AND USES THEREOF EP 83.6851 A 4f1998 GB 2457734 8, 2009 (75) Inventors: Joseph K. Rosentel, Jr., Johns Creek, WO WO 98,17277 4f1998 GA (US); Monica Tejwani, Monmouth WO WO O2/O94233 11, 2002 WO WO2004/O16252 2, 2004 Junction, NJ (US); Arima Das-Nandy, WO WO 2007/O18659 2, 2007 Titusville, NJ (US) WO WO 2008/O3O385 3, 2008 WO 2008/136791 11, 2008 (73) Assignee: MERLAL, INC., Duluth, GA (US) WO WO 2009/O18198 2, 2009 WO WO 2009/027506 3, 2009 WO 2009/112837 9, 2009 (*) Notice: Subject to any disclaimer, the term of this WO WO 2010/026370 3, 2010 patent is extended or adjusted under 35 WO WO2010.109214 9, 2010 U.S.C. 154(b) by 100 days. OTHER PUBLICATIONS (21) Appl. No.: 13/078,496 Notice of Opposition in the matter of New Zealand Patent Applica (22) Filed: Apr. 1, 2011 tion 595934 in the name of Norbrook Laboratories Limited and Opposition thereto by Merial Limited dated Jun. 28, 2014. (65) Prior Publication Data First Supplementary Notice of Opposition in the matter of New Zealand Patent Application 595934 in the name of Norbrook Labo US 2011 FO245191 A1 Oct. 6, 2011 ratories Limited and Opposition thereto by Merial Limited dated Aug. 28, 2014. Second Supplementary Notice of Opposition in the matter of New Related U.S.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,790,847 B2 Wach (45) Date of Patent: Sep
    USOO6790847B2 (12) United States Patent (10) Patent No.: US 6,790,847 B2 Wach (45) Date of Patent: Sep. 14, 2004 (54) TOPICAL APPLICATION OF CETIRIZINE JP O2835985 B 12/1998 AND LORATADNE WO WO9219276 A 11/1992 WO WO O1/39774 A1 6/2001 (75) Inventor: Hatto Walch, Baden (DE) WO WO 01/87236 A2 11/2001 OTHER PUBLICATIONS (73) Assignee: Oramon Arzneimittel GmbH, Laupheim (DE) International Search Report, Applin. No. 02000131.9-2123, dated Jun. 28, 2002. (*) Notice: Subject to any disclaimer, the term of this Origoni et al., “Topical oXatomide: an alternative approach patent is extended or adjusted under 35 for the treatment of vulvar lichen Sclerosus’, International U.S.C. 154(b) by 0 days. Journal of Gynecology and Obstetrics, 1996, pps. 259-264. Origoni et al., “Efficacy of Topical Oxatomide in Women (21) Appl. No.: 10/334,331 with Pruritus Vulvae”, Drugs. Exptl. Clin. Res., XVI (11), 1990, pps. 591-596. (22) Filed: Dec. 30, 2002 Sacerdoti et al., “Evalution of the inhibition of allergen-spe (65) Prior Publication Data cific and nonspecific skin responses by topical oXatomide,” G Ital Dermatol Venereol, vol. 125, No. 7-8, 1990, pps. US 2003/0129209 A1 Jul. 10, 2003 XXIX-XXXII. (30) Foreign Application Priority Data Lodi et al., “OXatomide in the treatment of pruriginous skin diseases of various nature', G Ital Dermatol Venereol, vol. Jan. 4, 2002 (EP) ............................................ O2OOO131 125, No. 10, 1990, pps. LV-LIX. Leggieri et al., “Topical oXatomide in the treatement of (51) Int. Cl." ........................ A61K 31/50; A61K 31/44; urticaria”, Reparto di Immunologia e Allergologia Clinica, A61K 31/445; A61K 31/74 1992, pps.
    [Show full text]